Title: Advanced unresectable hepatocellular carcinoma: new biologics as fresh ammunition or clues to disease understanding?
Authors: Dekervel, Jeroen ×
van Pelt, Jos
Verslype, Chris #
Issue Date: Jul-2013
Publisher: Rapid Science Publishers
Series Title: Current Opinion in Oncology vol:25 issue:4 pages:409-416
Article number: 10.1097/CCO.0b013e3283621074
Abstract: Hepatocellular carcinoma (HCC) is a prevalent malignancy associated with a guarded prognosis. At present, sorafenib is the only approved systemic therapy for patients with advanced disease. The effect of sorafenib on overall survival is modest and limited in time by the occurrence of drug resistance.
ISSN: 1040-8746
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Hepatology
× corresponding author
# (joint) last author

Files in This Item:

There are no files associated with this item.

Request a copy


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science